BURZYNSKI RESEARCH INSTITUTE INC
BZYR evidence brief
What we can confirm
- BioSniper Score:
- 4.0 / 10
- Market Cap:
- $263K
- Lead Asset:
- antineoplastons (Phase 3)
What it means
What to watch
Prepared research question
What matters most for BZYR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BZYR
Burzynski Research Institute Inc (BZYR) is a development-stage biotechnology company focused on obtaining FDA approval for its proprietary Antineoplaston therapy, primarily for brain tumors, with no revenue and funding reliant on its founder.
Key risk: No revenue and cash dependence
BioSniper Score
Based on 4 of 6 signals
Market Cap
$263K
Cash Runway
—
Lead Asset
antineoplastons (Phase 3)
Next Catalyst
Phase3_Start · Jun 1, 2027Financial data as of Nov 30, 2025.
Tracking 1 pipeline candidate · 3 clinical trials · 1 catalyst for BURZYNSKI RESEARCH INSTITUTE INC.
Burzynski Research Institute Inc (BZYR) is a development-stage biotechnology company focused on obtaining FDA approval for its proprietary Antineoplaston therapy, primarily for brain tumors, with no revenue and funding reliant on its founder.
- The company has generated no significant revenue since inception and does not expect revenues until FDA approval of Antineoplastons [sec_mda · as of 2025-05-20].
- As of November 30, 2025, the company reported $0.0 million in cash and equivalents, a net loss of $0.3 million, and negative shareholders' equity of $0.1 million [sec].
- The company's sole source of funding is Dr. Burzynski, who finances operations from his medical practice [sec_mda · as of 2025-05-20].
- A Phase 3 study of Antineoplastons (Atengenal and Astugenal) for newly diagnosed diffuse intrinsic brainstem glioma is planned to start on June 1, 2027 [upcoming catalysts].
What works
- The company has a targeted therapy (Antineoplastons) with a defined mechanism and an FDA-governed clinical development program for a serious condition — diffuse intrinsic brainstem glioma [catalyst].
What to weigh
- The company has no revenue and its sole source of funding is Dr. Burzynski's personal practice, creating a single-point dependency with no external capital [sec_mda · as of 2025-05-20].
- The company's financial position is extremely weak — cash of $0.0M and negative shareholder equity of $0.1M as of November 30, 2025 [sec].
- The company's only revenue, if any, would come from eventual FDA approval, which has not occured and may never occur [sec_mda · as of 2025-05-20].
From the filings
Quoted directly from source documents.
Company has no operating revenue and expects none until approval
“The Company has generated no significant revenue since its inception, and does not expect to generate any operating revenues until such time, if any, as Antineoplastons are approved for use and sale by the FDA.”
SEC MD&A · May 20, 2025
Funding source is Dr. Burzynski personally
“The Company's sole source of funding is Dr. Burzynski, who funds”
SEC MD&A · May 20, 2025
Catalyst timeline
- 2027-06-01 · Phase3_Start — Start of controlled Phase 3 evaluating Atengenal (A10) and Astugenal (AS2-1) for QT/QTc interval effect in newly diagnosed diffuse, intrinsic, brainstem glioma patients.
Risks & what to watch (4)›
Key risks
- No revenue and cash dependence — Company has no cash ($0.0M) and negative equity; operations depend on Dr. Burzynski's funding [sec_mda · as of 2025-05-20].
- No product approval or revenue timeline — No significant revenue exists, and none is 'til FDA approval, which may never happen [sec_mda · as of 2025-05-20].
- Clinical and regulatory uncertainty — Phase 3 study only planned to start June 2027; results and approval are uncertain and far [catalyst].
- Sole- person funding concentration — All funding relies on Dr. Burzynski's personal resources, creating a single point of failure [sec_mda· as of 2025-05-20].
What to watch
- Clinical: Initiation and enrollment start of the Phase 3 trial for diffuse intrinsic brainstem glioma, planned for June 1, 2027 [catalyst].
- Financial: Whether the Company can raise net cash or secure alternative funding to continue operations and support the Phase 3 study [sec_mda].
- Regulatory: Any communication from the FDA regarding the Phase 3 trial or path to approval for Antineoplastons [sec].
- Pipeline updates: Any data or announcements regarding the company's other potential Antineoplaston applications [no chunk].
Sources: SEC MD&A · Generated September 12, 2026 · How we verify sources →
Run BURZYNSKI RESEARCH INSTITUTE INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BURZYNSKI RESEARCH INSTITUTE INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$329K
Lead: Phase 3
1 candidate
1 upcoming, next in ~230d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for BURZYNSKI RESEARCH INSTITUTE INC?
Burzynski Research Institute Inc (BZYR) is a development-stage biotechnology company focused on obtaining FDA approval for its proprietary Antineoplaston therapy, primarily for brain tumors, with no revenue and funding reliant on its founder.
What is BURZYNSKI RESEARCH INSTITUTE INC's lead drug candidate?
BURZYNSKI RESEARCH INSTITUTE INC's most advanced tracked candidate is antineoplastons (Phase 3) for cancer.
What is BURZYNSKI RESEARCH INSTITUTE INC's next catalyst?
BURZYNSKI RESEARCH INSTITUTE INC's next tracked catalyst is a Phase3_Start event — "Phase3_Start: A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma" — expected June 1, 2027.
Who is the CEO of BURZYNSKI RESEARCH INSTITUTE INC?
Dr. Stanislaw R. Burzynski M.D., Ph.D. is the chief executive officer of BURZYNSKI RESEARCH INSTITUTE INC (BZYR).
Where is BURZYNSKI RESEARCH INSTITUTE INC headquartered?
BURZYNSKI RESEARCH INSTITUTE INC (BZYR) is headquartered in Houston, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.